Meloxicam: Selective COX-2 inhibition in clinical practice

Seminars in Arthritis and Rheumatism

Volumn 26, Issue 6 SUPPL. 1, 1997, Pages 21-27

  Furst, D E ^a  

^a BENAROYA RESEARCH INSTITUTE   (United States)

Author keywords

Gastrointestinal toxicity; NSAIDs; Osteoarthritis; Rheumatoid arthritis; Safety

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; MELOXICAM; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; PLACEBO; PROSTAGLANDIN E2;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TOXICITY; HUMAN; LIVER TOXICITY; NEPHROTOXICITY; OSTEOARTHRITIS; PEPTIC ULCER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; THROMBOCYTE AGGREGATION;

EID: 0030983255     PISSN: 00490172     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-0172(97)80049-2     Document Type: Article

References (24)

1. Pairet M. Engelhardt G. Distinct isoforms (COX-1 and COX-2) of cyclooxygenase: possible physiological and therapeutic implications Fundam Clin Pharmacol 10 1996 1 15
2. Engelhardt G. Bögel R. Schnitzler Chr. Utzmann R. Meloxicam: influence on arachidonic acid metabolism Biochem Pharmacol 51 1996 21 28
3. Meade B.A. Smith W.L. DeWitt D.L. Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs J Biol Chem 268 1993 6610 6614
4. Churchill L. Graham A.G. Shih C.-K. Pauletti D. Farina P.R. Grob P.M. Selective inhibition of human cyclo-oxygenase-2 by meloxicam Inflammopharmacology 4 1996 125 135
5. Glaser K. Sung M.L. O'Neill K. Etodolac selectively inhibits human prostaglandin G/H synthase 2 (PGHS-2) versus human PGHS-1 Eur J Pharmacol 281 1995 107 111
6. Glaser K.B. Cyclooxygenase selectivity and NSAIDs. Cyclooxygenase-2 selectivity of etodolac (Lodine) Inflammopharmacology 3 1995 335 345
7. (Abs P115) Patrignani P. Panara M.R. Santini G. Differential inhibition of the cyclooxygenase activity of prostaglandin endoperoxide synthase isozymes in vitro and ex vivo in man Prostaglandins Leukot Essent Fatty Acids 55 Suppl 1 1996 98
8. Patrignani P. Panara M.R. Greco A. Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases J Pharmacol Exp Ther 271 1994 1705 1712
9. Pairet M. Engelhardt G. Differential inhibition of COX-1 and COX-2 in vitro and pharmacological profile in vivo of NSAIDs Vane J. Botting J. Botting R. Improved non-steroid anti-inflammatory drugs-COX-2 Enzyme Inhibitors 1996 Kluwer Academic Publishing Dordrecht, Boston, London 103 119
10. Stichtenoth D.O. Wagner B. Frölich J.C. Effects of meloxicam and indomethacin on cyclooxygenase pathways in healthy volunteers Paper presented at the Biomedicine '96 meeting of the AAP, ASCI, and AFCR in Washington DC May 3–6 1996
11. Hosie J. Distel M. Bluhmki E. Meloxicam in osteoarthritis: a 6-month, double-blind comparison with diclofenac sodium Br J Rheumatol 35 Suppl 1 1996 39 43
12. Platt P.N. Recent clinical experience with etodolac in the treatment of osteoarthritis of the knee Clin Rheumatol 8 Suppl 1 1989 54 62
13. Lucker P.W. Pawlowski C. Friedrich I. Faiella F. Magni E. Double-blind, randomised, multi-centre clinical study evaluating the efficacy and tolerability of nimesulide in comparison with etodolac inpatients suffering from osteoarthritis of the knee Eur J Rheumatol Inflam 14 1994 29 38
14. Fleischmann R.M. Clinical efficacy and safety of nabumclone in rheumatoid arthritis and osteoarthritis J Rheumatol 19 Suppl 36 1992 32 40
15. Wojtulewski J.A. Schattenkirchner M. Barceló P. A six-month double-blind trial to compare the efficacy and safety of meloxicam 7.5 mg daily and naproxen 750 mg daily in patients with rheumatoidarthritis Br J Rheumatol 35 Suppl 1 1996 22 28
16. (Abstract 351) Huskisson E.C. Narjes H. Bluhmki E. Degner F. Comparison of meloxicam 15 mg and piroxicam 20 mg in a 3-week, double-blind trial in RA Eighth APLAR Congress of Rheumatology Melbourne 1996
17. Patoia L. Santucci L. Furno P. A 4-week, doubleblind, parallel-group study to compare the gastrointestinal effects of meloxicam 7.5 mg, meloxicam 15 mg, piroxicam 20 mg andplacebo by means of faecal blood loss, endoscopy and symptom evaluation in healthy volunteers Br J Rheumatol 35 Suppl 1 1996 61 67
18. Distel M. Mueller C. Bluhmki E. Fries J. Safety of meloxicam: a global analysis of clinical trials Br J Rheumatol 35 Suppl 1 1996 68 77
19. 1987 Jackson R.E. Mitchell F.N. Brindley D.A. Safety evaluation of nabumetone in United States clinical trials Am J Med 83 1987 115 120
20. Schmid J. Busch U. Trummlitz G. Prox A. Kaschke S. Wachsmuth H. Meloxicam: metabolic profile and biotransformation products in the rat Xenobiotica 25 1995 1219 1236
21. Türck D. Roth W. Busch U. A review of the clinical pharmacokinetics of meloxicam Br J Rheumatol 35 Suppl 1 1996 13 16
22. Bevis P.F.R. Bird H.A. Lapham G. An open study to assess the safety and tolerability of meloxicam 15 mg in subjects with rheumatic disease and mild renal impairment Br J Rheumatol 35 Suppl 1 1996 56 60
23. Shand D.G. Epstein C. Kinberg-Calhoun J. Mullane J.F. Sanda M. The effect of etodolac administration on renal function in patients with arthritis J Clin Pharmacol 26 1986 269 274
24. Aronoff G.R. Therapeutic implications associated with renal studies of nabumetone J Rheumatol 19 Suppl 36 1992 25 31